Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.66 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)699.12K
Market Cap
$1.93B
Enterprise Value$1.65B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)3.0
Beta1.91
Next Earnings
May 01, 2025EPS Estimate
-1.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding57,296,165
10 Day Avg. Volume708,096
30 Day Avg. Volume699,116
Standard Deviation0.14
R-Squared0.10
Alpha-0.00574
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)59.30
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit51.10
Enterprise Value/Ebitda-3.92
Forecast
1Y Price Target
$59.00Price Target Upside74.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Agios Pharma News
PremiumCompany Announcements
Agios Pharmaceuticals Reports Strong 2024 Financial Results
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress
PremiumCompany Announcements
Agios Pharma Board Member Announces Resignation---
Bulls Say, Bears Say
Bulls Say
International ExpansionAgios has completed thalassemia regulatory filings for mitapivat in the EU, Saudi Arabia, and UAE.
Regulatory MilestonesMitapivat's sNDA is under review with the FDA with a PDUFA date set, and launch preparation is ongoing.
Bears Say
Safety ConcernsThe updated label for Pyrukynd includes a warning for liver injury, which has been an overhang for AGIO shares, contributing to a significant decline in stock value.
---
Ownership Overview
1.50% Insiders
26.28% Mutual Funds
0.08% Other Institutional Investors
54.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $26.66 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.93B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Feb 13, 2025. The company reported -$1.44 earnings per share for the quarter, beating the consensus estimate of -$1.691 by $0.251.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.76.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 57,296,165 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.44 in its last earnings report, beating expectations of -$1.691. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
---
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.00 (74.81% Upside)
$59.00 (74.81% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 105.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.2%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.53%
12-Months-Change
Fundamentals
Return on Equity
57.29%
Trailing 12-Months
Asset Growth
77.48%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
AGIO Company Deck
---
AGIO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development pipeline, with major milestones expected in thalassemia and sickle cell disease. Strong revenue growth from PYRUKYND and a robust financial position are positive indicators. However, higher operating expenses and limited revenue growth for PK deficiency were noted as challenges.Read More>---
AGIO Stock 12 Month Forecast
Average Price Target
$59.00
▲(74.81% Upside)
Technical Analysis
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+17.85%
reiterated a buy rating 9 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +17.85% per trade.
---